预约演示
更新于：2026-02-27
Roxithromycin
罗红霉素
更新于：2026-02-27
概要
基本信息
原研机构- |
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 中国 (1989-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C41H76N2O15 |
InChIKeyRXZBMPWDPOLZGW-XMRMVWPWSA-N |
CAS号80214-83-1 |
关联
28
项与 罗红霉素 相关的临床试验CTR20253181
罗红霉素片在健康参与者中的单中心、随机、开放、两制剂、单次给药、两序列、 四周期、 完全重复交叉空腹状态下生物等效性试验
CTR20252849
罗红霉素片（0.15g）在中国健康受试者中空腹给药条件下随机、开放、单剂量、两序列、两周期、双交叉生物等效性试验
CTR20250927
中国健康受试者空腹状态下口服罗红霉素胶囊的单中心、随机、开放、两序列、两周期、双交叉生物等效性试验
100 项与 罗红霉素 相关的临床结果
登录后查看更多信息
100 项与 罗红霉素 相关的转化医学
登录后查看更多信息
100 项与 罗红霉素 相关的专利（医药）
登录后查看更多信息
3,081
项与 罗红霉素 相关的文献（医药）2026-05-01JOURNAL OF VIROLOGICAL METHODS
Prevalence and ribavirin-mediated elimination of Morchella importuna endornavirus 1 (MiEV1) in cultivated Morchella species in China
Article
作者: Wang, Zhaoyu ; Li, Yankui ; Shang, Zengqiang ; Peng, Ziyan ; Zhang, Yingjun ; Zhang, Zhifeng ; Zhao, Longbo ; Wang, Xiaoli
Fungal viruses compromise the cultivation of Morchella. We surveyed five mycoviruses (Morchella importuna endornavirus 1 [MiEV1], Morchella importuna endornavirus 2 [MiEV2], Morchella importuna endornavirus 3 [MiEV3], Morchella esculenta fusarivirus 1 [MeFV1], and Morchella esculenta fusarivirus 2 [MeFV2]) in 24 cultivated strains (8 M. importuna, 5 M. septimelata, and 11 M. sextelata) collected across 11 provinces in China and evaluated candidate antiviral agents. Only MiEV1 was detected, with a high incidence of 79.2 % (19/24) across all three Morchella species. Among seven tested chemicals (ampicillin, azithromycin, kanamycin, rifampicin, roxithromycin, acyclovir hydrochloride, and ribavirin), only ribavirin significantly inhibited MiEV1 replication. Successive ribavirin treatments eliminated MiEV1 from a representative M. sextelata strain (M11), with the virus-free status remaining stable after multiple subcultures on drug-free medium. Elimination of MiEV1 also significantly enhanced mycelial growth rate and biomass, and led to enhanced mycelial pigmentation, suggesting a potential negative impact of MiEV1 on vegetative growth and pigmentation in M. sextelata. These findings demonstrate that MiEV1 is prevalent in cultivated Morchella and that ribavirin provides an effective strategy for generating stable virus-free strains, offering opportunities for mechanistic studies and industrial cultivation.
2026-02-01CHEMOSPHERE
Impact of ions co-occurring in water on antibiotics degradation by UV-based advanced oxidation process
Article
作者: van de Merwe, Jason ; Kelso, Celine ; Bin Khalid, Zaied ; Hai, Faisal I
The pollution of natural water sources with antibiotics is an emerging environmental concern. This study evaluated the degradation efficiency of nine antibiotics in a mixed solution under different UV-based advanced oxidation processes. In the UV-only treatment, ciprofloxacin, cefalexin, and ceftiofur were fully degraded within 5 min, meropenem within 10 min, and penicillin G, roxithromycin, oxytetracycline, doxycycline, and sulfamethazine within 30 min. The effects of inorganic ions and organic matter were investigated due to their significant influence on the degradation performance of antibiotics. Chloride ion, sulfate ion, and humic acid negatively affected degradation, reducing mean degradation efficiency over a period of 15 min to 60-80 %, 57-97 %, and 74-79 %, respectively. In contrast, nitrate, phosphate, and bicarbonate enhanced degradation, with mean degradation efficiency exceeding 95 %. To further enhance the degradation efficiency, UV-based oxidants (persulfate, peroxide, and chlorine) were applied, achieving 95-100 % degradation within 15 min, except for roxithromycin, which required a longer incubation period for complete degradation. A bioluminescence assay showed relatively low acute toxicity of the antibiotics before and after treatments, with a maximum of 4.1 rTU observed during the UV/chlorine process in the presence of co-occurring ions. Notably, this is the first study to report on antibiotic degradation under realistic concentrations of antibiotics and co-occurring ions, demonstrating that the UV/chlorine process offers the most effective performance for antibiotic degradation.
2026-01-08Journal of Physical Chemistry Letters
Heat Capacity Signature Resembling the Glass Transition in Crystalline Solids: Challenging the Classical View of Melting
Article
作者: Pyda, Marek ; Skotnicki, Marcin ; Czerniecka-Kubicka, Anna ; Cebe, Peggy
Melting and glass transitions are classically viewed as distinct phenomena, the former in crystalline materials and the latter in amorphous systems. Here we show that fully crystalline, low-molecular-weight solids can display heat-capacity changes during melting that closely mimic those seen at the glass transition. Using temperature-modulated differential scanning calorimetry, we detect continuous, reversible steps in heat capacity in crystalline roxithromycin and glucose that mirror those of their amorphous counterparts. Similar behavior is observed during the crystallization of semicrystalline poly(3-hydroxybutyrate). These findings provide direct experimental evidence for a transition exhibiting a Cp signature similar in shape and magnitude to that observed at the glass transition, a transition-like thermodynamic signature in the melting of crystalline materials. This discovery expands the conceptual boundary of glass transitions and suggests that large-amplitude molecular motions underlie both melting and vitrification.
100 项与 罗红霉素 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 急性支气管炎 | 澳大利亚 | 2004-03-30 | |
| 急性咽炎 | 澳大利亚 | 2004-03-30 | |
| 急性扁桃体炎 | 澳大利亚 | 2004-03-30 | |
| 慢性支气管炎 | 澳大利亚 | 2004-03-30 | |
| 社区获得性肺炎 | 澳大利亚 | 2004-03-30 | |
| 脓疱疮 | 澳大利亚 | 2004-03-30 | |
| 下呼吸道感染 | 澳大利亚 | 2004-03-30 | |
| 非淋菌性尿道炎 | 澳大利亚 | 2004-03-30 | |
| 呼吸道感染 | 澳大利亚 | 2004-03-30 | |
| 扁桃体炎 | 澳大利亚 | 2004-03-30 | |
| 寻常痤疮 | 日本 | 1991-01-18 | |
| 喉炎 | 日本 | 1991-01-18 | |
| 淋巴结炎 | 日本 | 1991-01-18 | |
| 咽炎 | 日本 | 1991-01-18 | |
| 肺炎 | 日本 | 1991-01-18 | |
| 鼻窦炎 | 日本 | 1991-01-18 | |
| 皮肤和皮肤结构感染 | 日本 | 1991-01-18 | |
| 感染 | 中国 | 1989-01-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 124 | 廠積繭壓構築齋鑰願積(夢選網鹽簾範簾顧顧繭): OR = 3.69 (95% CI, 1.175 ~ 11.607), P-Value = 0.025 | - | 2023-02-01 | |||
临床4期 | 100 | 鬱糧鏇遞網衊遞鑰顧網(齋繭顧積夢網製鏇蓋淵) = 壓構顧鬱獵簾範醖鬱蓋 觸構壓製夢願鬱範簾憲 (顧範觸壓選廠壓壓齋觸 ) 更多 | 积极 | 2011-09-01 | |||
Placebo | 鬱糧鏇遞網衊遞鑰顧網(齋繭顧積夢網製鏇蓋淵) = 觸齋繭淵鑰糧蓋鹽淵遞 觸構壓製夢願鬱範簾憲 (顧範觸壓選廠壓壓齋觸 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用